Provided by Tiger Fintech (Singapore) Pte. Ltd.

CSTONE PHARMA-B

2.760
+0.2509.96%
Volume:4.81M
Turnover:12.87M
Market Cap:3.76B
PE:-36.43
High:2.780
Open:2.540
Low:2.540
Close:2.510
Loading ...

CStone Pharmaceuticals Carries Out First Dosing in Multi-Cancer Drug Trial

MT Newswires Live
·
04 Mar

CStone Announces First Patient Dosed in Global Multicenter Phase I Clinical Trial of Cs2009, a Pd-1/Vegf/Ctla-4 Trispecific Antibody

THOMSON REUTERS
·
04 Mar

There's No Escaping CStone Pharmaceuticals' (HKG:2616) Muted Revenues Despite A 28% Share Price Rise

Simply Wall St.
·
15 Feb

CStone Pharmaceuticals' Lung Cancer Drug Included in ESMO Living Guideline

MT Newswires Live
·
10 Feb

CStone Announces Inclusion of Cejemly® (Sugemalimab) as a First-Line Combination Therapy for Nsclc in Esmo Guideline

THOMSON REUTERS
·
10 Feb

CStone Pharmaceuticals - Announces Inclusion of Sugemalimab (Cejemly®) as First-Line Combination Therapy for Nsclc

THOMSON REUTERS
·
10 Feb

CStone Pharmaceuticals Partners Up with Latin American Pharmaceutical Firm

MT Newswires Live
·
03 Feb

CStone Pharmaceuticals - CStone and Steincares Enter Into Partnership to Market Sugemalimab in Latin America

THOMSON REUTERS
·
27 Jan

CStone Pharmaceuticals Submits Application for Solid Tumor Drug Trials in Australia

MT Newswires Live
·
23 Dec 2024

CStone Announces Submission of Clinical Trial Application in Australia for Cs2009, an Innovative Pd-1/Vegf/Ctla-4 Trispecific Antibody

THOMSON REUTERS
·
23 Dec 2024

CStone Pharmaceuticals Enrolls First Patient in Phase 1B Trial for Anti-Tumor Drug

MT Newswires Live
·
19 Dec 2024

Is CStone Pharmaceuticals (HKG:2616) Weighed On By Its Debt Load?

Simply Wall St.
·
12 Dec 2024

CStone Pharmaceuticals Grants Commercial Rights of Tumor Drug for MENA Region to UAE Firm

MT Newswires Live
·
21 Nov 2024

BRIEF-Cstone Pharmaceuticals & Pharmalink Enter Into Strategic Partnership For Sugemalimab

Reuters
·
21 Nov 2024

CStone Pharmaceuticals - Under Partnership Pharmalink Will Gain Commercial Rights for Sugemalimab in Middle East, Others

THOMSON REUTERS
·
21 Nov 2024

CStone Pharmaceuticals - CStone & Pharmalink Enter Into Strategic Partnership for Sugemalimab in Middle East, North Africa Region & South Africa

THOMSON REUTERS
·
21 Nov 2024

CStone Drug Gets UK Approval for First-Line Treatment of Non-Small Cell Lung Cancer

MT Newswires Live
·
31 Oct 2024

CStone Announces Mhra Approval of Sugemalimab for First-Line Treatment of Non-Small Cell Lung Cancer (Nsclc) in the UK

THOMSON REUTERS
·
31 Oct 2024

Insiders Buying CStone Pharmaceuticals Might Wish They Invested More, Stock Gains 14%

Simply Wall St.
·
31 Oct 2024

BRIEF-Cstone Pharmaceuticals Receives MHRA Approval Of Sugemalimab For First-Line Treatment Of Non-Small Cell Lung Cancer In UK

Reuters
·
31 Oct 2024